Found 1 Presentation For Request "615p"
615P - Circulating tumor cells (CTC) gene expression and plasma androgen receptor (AR) copy number (CN) in cabazitaxel-treated metastatic castration-resistant prostate cancer (mCRPC)
- Giorgia Gurioli (Meldola, Italy)
Abstract
Background
Cabazitaxel showed overall survival (OS) benefit for mCRPC patients (pts) progressing after docetaxel. In a prospective study (NCT03381326), we evaluated the role of CTC gene expression of cabazitaxel-treated pts and its association with plasma
Methods
We enrolled 100 mCRPC pts receiving cabazitaxel 20 or 25 mg/sqm from December 2014 to December 2018. Baseline plasma DNA was isolated and digital PCR was performed to assess
Results
Seventy-four pts were fully evaluable for this analysis. CTC expression of AR-V7 (hazard ratio [HR]=2.52, 95% CI 1.24-5.12, p=0.011), AKR1C3 (HR=2.01, 95% CI 1.06-3.81, p=0.031), AR (HR=2.70, 95% CI 1.46-5.01, p=0.002), EPCAM (HR=3.75, 95% CI 2.10-6.71, p<0.0001), PSMA (HR=2.09, 95% CI 1.19-3.66, p=0.01), MDK (HR=3.35, 95% CI 1.83-6.13, p<0.0001) and HPRT1 (HR=2.46, 95% CI 1.44-4.18, p=0.0009) was associated with shorter OS in univariate analysis. ALDH1 (odds ratio [OR]=5.50, 95% CI 0.97-31.22, p=0.05), AR (OR=8.71, 95% CI 2.32-32.25, p=0.001), EPCAM (OR=7.26, 95% CI 1.47-35.73, p=0.015), PSMA (OR=3.86, 95% CI 1.10-13.50, p=0.035), MDK (OR=6.84, 95% CI 1.87-24.98, p=0.004) and HPRT1 (OR=7.41, 95% CI 1.82-30.19, p=0.005) expression was associated with early disease progression within the first three months.
Conclusions
Baseline CTC biomarkers may be considered useful prognosticators for cabazitaxel-treated mCRPC pts. Our results suggest that cabazitaxel 25 mg/sqm should be preferred in AR-V7-pos mCRPC.
Clinical trial identification
NCT03381326.
Legal entity responsible for the study
The authors.
Funding
Partially funded by Sanofi Genzyme.
Disclosure
G. Gurioli: Other, Institutional, Other, Travel support: Sanofi Genzyme. V. Conteduca: Other, Institutional, Advisory Board: Janssen; Other, Institutional, Advisory Board: Astellas; Other, Institutional, Advisory Board: Merck; Other, Institutional, Advisory Board: AstraZeneca; Other, Institutional, Advisory Board: Bayer; Other, Institutional, Other, travel support: Ipsen; Other, Institutional, Other, travel support: Sanofi Genzyme. N. Brighi: Other, Institutional, Other, Travel support: Pfizer; Other, Institutional, Other, Travel support: Ipsen; Other, Institutional, Other, Travel support: Novartis. G. Fornarini: Other, Institutional, Advisory Role: Ipsen; Other, Institutional, Advisory Role: Sanofi Genzyme; Other, Institutional, Advisory Role: BMS; Other, Institutional, Advisory Role: Pfizer; Other, Institutional, Advisory Role: Janssen; Other, Institutional, Advisory Role: MSD; Other, Institutional, Advisory Role: Novartis. M. Nicodemo: Other, Institutional, Other: Bristol-Myers Squibb; Other, Institutional, Other: Ipsen; Other, Institutional, Other: Molteni; Other, Institutional, Other: Janssen. G.L. Banna: Other, Personal, Other: Janssen-Cilag; Other, Personal, Other: Boehringer Ingelheim; Other, Personal, Other: Roche; Other, Personal, Other: AstraZeneca/MedImmune. C. Lolli: Other, Institutional, Advisory Board: Bristol-Myers Squibb; Other, Institutional, Advisory Board: Janssen-Cilag. U. De Giorgi: Other, Institutional, Advisory Board: Astellas; Other, Institutional, Advisory Board: Bayer; Other, Institutional, Advisory Board: BMS; Other, Institutional, Advisory Board: Ipsen; Other, Institutional, Advisory Board: Janssen; Other, Institutional, Advisory Board: Merck; Other, Institutional, Advisory Board: Pfizer; Other, Institutional, Advisory Board: Sanofi Genzyme; Other, Institutional, Research Grant: AstraZeneca; Other, Institutional, Research Grant: Roche. All other authors have declared no conflicts of interest.